CG Oncology, Inc. Common stock (CGON)vsInsmed Inc (INSM)
CGON
CG Oncology, Inc. Common stock
$65.81
+3.09%
HEALTHCARE · Cap: $5.39B
INSM
Insmed Inc
$148.31
+6.59%
HEALTHCARE · Cap: $29.99B
Smart Verdict
WallStSmart Research — data-driven comparison
Insmed Inc generates 14910% more annual revenue ($606.42M vs $4.04M). CGON leads profitability with a 0.0% profit margin vs -2.1%. INSM earns a higher WallStSmart Score of 39/100 (F).
CGON
Avoid32
out of 100
Grade: F
INSM
Hold39
out of 100
Grade: F
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Safe zone — low bankruptcy risk
No standout strengths identified
Areas to Watch
4.1% revenue growth
0.0% earnings growth
0.0% margin — thin
ROE of -21.7% — below average capital efficiency
1.5% revenue growth
0.0% earnings growth
Trading at 43.0x book value
ROE of -2.5% — below average capital efficiency
Comparative Analysis Report
WallStSmart ResearchBull Case : CGON
The strongest argument for CGON centers on Altman Z-Score.
Bull Case : INSM
PEG of 1.09 suggests the stock is reasonably priced for its growth.
Bear Case : CGON
The primary concerns for CGON are Revenue Growth, EPS Growth, Profit Margin.
Bear Case : INSM
The primary concerns for INSM are Revenue Growth, EPS Growth, Price/Book.
Key Dynamics to Monitor
CGON profiles as a value stock while INSM is a turnaround play — different risk/reward profiles.
CGON carries more volatility with a beta of 1.19 — expect wider price swings.
CGON is growing revenue faster at 4.1% — sustainability is the question.
CGON generates stronger free cash flow (-36M), providing more financial flexibility.
Bottom Line
INSM scores higher overall (39/100 vs 32/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
CG Oncology, Inc. Common stock
HEALTHCARE · BIOTECHNOLOGY · USA
CG Oncology, Inc. is a clinical-stage biotechnology company focused on innovating cancer therapies, with its lead asset, CG0070, being an oncolytic virus therapy designed specifically for non-muscle invasive bladder cancer. The company's strategic commitment to addressing significant unmet needs in oncology emphasizes its potential impact on patient outcomes and treatment paradigms. As CG Oncology progresses through clinical trials and approaches key regulatory milestones, it leverages its proprietary platform to position itself favorably in the competitive oncology landscape. This strategic focus on pioneering therapeutic solutions presents a compelling opportunity for institutional investors seeking to invest in transformative advancements in cancer care.
Insmed Inc
HEALTHCARE · BIOTECHNOLOGY · USA
Insmed Incorporated, a biopharmaceutical company, develops and markets therapies for patients with rare and serious diseases. The company is headquartered in Bridgewater, New Jersey.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?